CING
CingulateDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Patent issuance plus successful manufacturing scale-up and favorable commercial data/partnerships drive re-rating toward higher analyst targets; scenario assumes commercial optionality materializes and interest from specialty pharma/partners.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
Clinical/regulatory setbacks for CTx-1301
Momentum
5
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.50 · Bull $17.00 · Bear $4.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $29.25
Why
Momentum5 · Δ7d -1.8
Value41 · Δ7d +0.1
Sentiment100 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
5
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.8
Δ21d
+0.7
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 5.1 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$48.49M
Beta
-0.77
Shares Out
6.76M
P/E (TTM) · Derived
-0.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.68
Rev YoY
-
EPS YoY
+42.1%
Gross Margin
-
Op Margin
-
Net Debt
-$7.24M
Current Ratio
1.26
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology